Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Thiemermann

Showing results (1-10 of 293) with videos related to

Pageof 30
Sort By:
Critical Care Medicine|January 25, 2003
Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammationChristoph Thiemermann
Shock (Augusta, Ga.)|July 17, 2024
CORRECTION FOR: THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ LIGAND 15-DEOXYΔ12,14 PROSTAGLANDIN J2 REDUCES THE ORGAN INJURY IN HEMORRHAGIC SHOCKChristoph Thiemermann
Shock (Augusta, Ga.)|February 19, 2008
What's new in shock, March 2008Christoph Thiemermann
Shock (Augusta, Ga.)|April 30, 2024
CORRECTION TO: THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ LIGAND 15-DEOXYΔ12,14 PROSTAGLANDIN J2 REDUCES THE ORGAN INJURY IN HEMORRHAGIC SHOCKChristoph Thiemermann
Cardiovascular Research|June 15, 2004
Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct sizeChristoph Thiemermann
British Journal of Pharmacology|August 12, 2004
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failureChristoph Thiemermann
Critical Care Medicine|May 15, 2002
Development of novel, water-soluble inhibitors of poly (adenosine 5'-diphosphate ribose) synthetase activity for use in shock and ischemia-reperfusion injuryChristoph Thiemermann
Critical Care (London, England)|June 5, 2007
Beneficial effects of erythropoietin in preclinical models of shock and organ failureChristoph Thiemermann
Shock (Augusta, Ga.)|August 19, 2008
What's new in Shock, September 2008?Christoph Thiemermann
Critical Care Medicine|February 11, 2003
Protein tyrosine kinase inhibitors as novel therapeutics for systemic inflammation, shock, and organ injuryChristoph Thiemermann
Pageof 30

Showing results (1-10 of 293) with videos related to

Sort By:
Pageof 30
Critical Care Medicine|January 25, 2003
Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammationChristoph Thiemermann
Shock (Augusta, Ga.)|July 17, 2024
CORRECTION FOR: THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ LIGAND 15-DEOXYΔ12,14 PROSTAGLANDIN J2 REDUCES THE ORGAN INJURY IN HEMORRHAGIC SHOCKChristoph Thiemermann
Shock (Augusta, Ga.)|February 19, 2008
What's new in shock, March 2008Christoph Thiemermann
Shock (Augusta, Ga.)|April 30, 2024
CORRECTION TO: THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ LIGAND 15-DEOXYΔ12,14 PROSTAGLANDIN J2 REDUCES THE ORGAN INJURY IN HEMORRHAGIC SHOCKChristoph Thiemermann
Cardiovascular Research|June 15, 2004
Inhibition of the activation of nuclear factor kappa B to reduce myocardial reperfusion injury and infarct sizeChristoph Thiemermann
British Journal of Pharmacology|August 12, 2004
Ligands of the peroxisome proliferator-activated receptor-gamma and heart failureChristoph Thiemermann
Critical Care Medicine|May 15, 2002
Development of novel, water-soluble inhibitors of poly (adenosine 5'-diphosphate ribose) synthetase activity for use in shock and ischemia-reperfusion injuryChristoph Thiemermann
Critical Care (London, England)|June 5, 2007
Beneficial effects of erythropoietin in preclinical models of shock and organ failureChristoph Thiemermann
Shock (Augusta, Ga.)|August 19, 2008
What's new in Shock, September 2008?Christoph Thiemermann
Critical Care Medicine|February 11, 2003
Protein tyrosine kinase inhibitors as novel therapeutics for systemic inflammation, shock, and organ injuryChristoph Thiemermann
Pageof 30